CJC-1295 NO-DAC 2mg (MOD GRF 1-29)

CJC-1295 NO-DAC Peptide for In Vitro Research – CJC-1295 NO-DAC is a synthetic peptide, featuring the first 29 amino acids of growth hormone-releasing hormone (GHRH), also called modified growth releasing factor 1-29 (MOD GRF 1-29).¹ This peptide has a molecular weight of approximately 3.4 kDa and retains all essential features of GHRH, making it an ideal choice for in vitro studies on growth and development.²

The unique feature of CJC-1295 NO-DAC is the absence of a Drug Affinity Complex (DAC), which promotes a more physiological response in controlled lab environments. Designed using a Human GRF template, this peptide incorporates modified amino acids that enhance stability, such as substituting the first two amino acids to prevent peptidase metabolism in cell cultures.^3,4 With an extended half-life of around 30 minutes, CJC-1295 demonstrates improved stability over unmodified GHRH, making it suitable for longer-duration in vitro research.³

In animal models, CJC-1295 has shown significant impacts on growth and metabolic functions. For example, GHRH knockout mice administered daily doses of CJC-1295 for five weeks achieved normal body weight and length, showing comparable growth to control groups.¹ In addition, CJC-1295 is used to investigate growth hormone deficiencies in obese rat models, which has broadened its application in metabolic and growth-related research.⁵ Studies also suggest that MOD GRF has superior pharmacokinetic and pharmacodynamic properties compared to endogenous GHRH, enhancing its effectiveness in laboratory studies of growth, development, and metabolic disorders such as diabetes.⁴

Product Information: CJC-1295 NO-DAC is provided as a 2 mg lyophilized powder in a vial, intended strictly for in vitro laboratory research and not suitable for human or animal application outside controlled research settings.

References:
1. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4.
2. Matsoukas MT, Spyroulias GA. Dynamic properties of the growth hormone-releasing hormone receptor (GHRHR) and molecular determinants of GHRH binding. Mol Biosyst. 2017 Jun 27;13(7):1313-1322.
3. Campbell RM, Stricker P, Miller R, Bongers J, Liu W, Lambros T, Ahmad M, Felix AM, Heimer EP. Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides. 1994;15(3):489-95.
4. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8.
5. Renier G, Gaudreau P, Deslauriers N, Petitclerc D, Brazeau P. Dynamics of the GRF-induced GH response in genetically obese Zucker rats: influence of central and peripheral factors. Regul Pept. 1990 Mar 27;28(1):95-106.